Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.

Oncologist · 2020 · PMC7160412 · PMID 32297446

Europe PMC DOI

hedged sentence

0.0980

closest p · 2.0× alpha

0.0980

boldest claim

The sentences

showed a trendp = .098so close (0.05 < p ≤ 0.1)

The PFS showed a trend toward a better PFS for patients treated with an intended dose of 9 g/m 2 ( p = .098; Fig. 2 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.